--- title: "Pharmaceutical Formulation Development" id: "2080" type: "page" slug: "pharmaceutical-formulation-development" published_at: "2026-11-06T12:32:20+00:00" modified_at: "2026-11-06T12:32:20+00:00" url: "https://innocorepharma.com/pharmaceutical-formulation-development/" markdown_url: "https://innocorepharma.com/pharmaceutical-formulation-development.md" --- # Pharmaceutical Formulation Development Pharmaceutical formulation development translates the properties of an active pharmaceutical ingredient (API) into a dosage form with defined quality and performance characteristics. For peptides and biologics, this requires careful consideration of molecular stability, formulation composition, drug loading and the conditions used during processing and release. Innocore supports pharmaceutical and biotechnology companies developing polymer-based formulations, with particular expertise in sustained-release applications. Combining formulation science with its proprietary SynBiosys® biodegradable polymer platform, Innocore investigates formulation approaches based on the characteristics of the API and its target product profile. ## Formulation development starts with the molecule Effective **drug delivery development** requires an understanding of the API before a suitable formulation can be selected. Molecular size, solubility, stability and sensitivity to processing conditions can influence which excipients, polymer systems and manufacturing methods are appropriate. These properties are evaluated against the target product profile, including the required dose, intended administration route, release characteristics and relevant quality attributes. For peptides and biologics, early formulation work may need to investigate molecular integrity under different processing and formulation conditions. The objective is to identify combinations of materials and processing parameters that warrant further development. ## Addressing formulation challenges for peptides and biologics Peptides and biologics can be sensitive to changes in their physical and chemical environment. Depending on the molecule, formulation conditions may influence aggregation, fragmentation or other changes in molecular integrity. For sustained-release systems, these considerations extend beyond initial preparation. The API may remain within a delivery matrix for an extended period, during which water uptake, swelling and polymer degradation can alter its local environment. Formulation development must therefore consider the relationship between API stability and the intended release behavior. Encapsulation within a polymer matrix does not automatically preserve molecular integrity; compatibility must be established experimentally. ## Key parameters in pharmaceutical formulation development Formulation optimization involves balancing several connected parameters. Improving one characteristic may influence another, making it important to evaluate candidate formulations against the complete target product profile. | Formulation parameter | Development consideration | | --- | --- | | API stability | Maintaining relevant molecular quality attributes during processing, storage and release. | | Excipient and polymer compatibility | Understanding interactions between the API and formulation materials. | | Drug loading | Accommodating the intended dose while maintaining suitable formulation characteristics. | | Release behavior | Evaluating whether the formulation approaches the intended release profile. | | Physical characteristics | Assessing attributes such as particle size, morphology, viscosity or matrix structure, depending on the dosage form. | | Process compatibility | Understanding how preparation and processing conditions influence formulation quality. | ## Formulation development using SynBiosys® Innocore’s proprietary SynBiosys® platform uses biodegradable multi-block copolymers with hydrophilic and hydrophobic domains. The hydrophilic, PEG-containing domains absorb water and swell, while hydrophobic crystalline domains provide physical cross-links that contribute to matrix integrity. This architecture provides a basis for investigating how polymer composition and formulation parameters influence API incorporation, matrix behavior and sustained release. For **long-acting injectable development**, relevant formulation characteristics may include drug loading, initial release, API integrity and the reproducibility of the intended release profile. The appropriate polymer composition and formulation approach depend on the API. Candidate formulations must be evaluated experimentally rather than assuming that platform characteristics will produce the same results for different molecules. ## From formulation screening to optimization Early formulation screening is used to compare candidate compositions and identify the parameters most likely to influence product performance. Depending on the program, this may involve investigating different polymer compositions, API concentrations or processing conditions. Analytical results guide subsequent optimization. Through **analytical development**, relevant methods can be established to evaluate API content, molecular integrity, physical attributes and release characteristics. Formulation optimization is an iterative process. A change intended to improve drug loading, for example, may also affect matrix structure or release behavior. Each adjustment must therefore be assessed against the requirements of the intended product. ## Discuss your pharmaceutical formulation development program [Contact Innocore](https://innocorepharma.com/contact-us/) ## Considering manufacturability during formulation development A formulation must be suitable not only for laboratory evaluation but also for further manufacturing development. Processing conditions can influence critical product attributes, even when the nominal formulation composition remains unchanged. Through **process development**, relevant manufacturing parameters can be investigated for their effects on formulation characteristics, reproducibility and potential scalability. Considering these requirements during formulation optimization helps development teams identify limitations before progressing toward larger-scale manufacturing or technology transfer. ## Frequently asked questions about pharmaceutical formulation development What is pharmaceutical formulation development? + Pharmaceutical formulation development involves selecting and optimizing the composition and preparation of a dosage form to meet defined product requirements. It includes evaluating API compatibility, stability, drug loading, physical characteristics and performance. Why is formulation development challenging for biologics? + Biologics may be sensitive to processing conditions and changes in their formulation environment. Development must consider molecular integrity alongside the intended characteristics of the dosage form. What is the difference between formulation development and process development? + Formulation development focuses on the composition and characteristics of the dosage form. Process development focuses on the manufacturing operations and parameters required to produce that formulation reproducibly. The two activities are closely connected. How is formulation stability evaluated? + Stability is assessed using analytical methods appropriate to the API and formulation. Depending on the molecule, testing may investigate changes in molecular integrity, API content or other relevant quality attributes under defined conditions. ## Discuss your pharmaceutical formulation development program Developing a pharmaceutical formulation requires a coordinated understanding of API properties, material compatibility, product performance and manufacturing requirements. Innocore combines formulation science, polymer expertise and analytical capabilities to support sustained-release formulation development for peptides and biologics. Contact Innocore to discuss the formulation requirements and technical challenges of your API. [Contact Innocore](https://innocorepharma.com/contact-us/)